1. Dose de‐escalation to adalimumab 40 mg every 3 weeks in patients with Crohn's disease – a nested case–control study. Issue 7 (6th February 2017) Authors: Van Steenbergen, S.; Bian, S.; Vermeire, S.; Van Assche, G.; Gils, A.; Ferrante, M. Journal: Alimentary pharmacology & therapeutics Issue: Volume 45:Issue 7(2017) Page Start: 923 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗